Therapeutic effect of erythropoietin in patients with traumatic brain injury: a meta-analysis of randomized controlled trials
- PMID: 27367243
- DOI: 10.3171/2016.4.JNS152909
Therapeutic effect of erythropoietin in patients with traumatic brain injury: a meta-analysis of randomized controlled trials
Abstract
OBJECTIVE Erythropoietin (EPO) exerts a neuroprotective effect in animal models of traumatic brain injury (TBI). However, its effectiveness in human patients with TBI is unclear. In this study, the authors conducted the first meta-analysis to assess the effectiveness and safety of EPO in patients with TBI. METHODS In December 2015, a systematic search was performed of PubMed, Web of Science, MEDLINE, Embase, the Cochrane Library databases, and Google Scholar. Only English-language publications of randomized controlled trials (RCTs) using EPO in patients with TBI were selected for analysis. The assessed outcomes included mortality, favorable neurological outcome, hospital stay, and associated adverse effects. Continuous variables were presented as mean difference (MD) with a 95% confidence interval (CI). Dichotomous variables were presented as risk ratio (RR) or risk difference (RD) with a 95% CI. Statistical heterogeneity was examined using both I2 and chi-square tests. RESULTS Of the 346 studies identified in the search, 5 RCTs involving 915 patients met the inclusion criteria. The overall results demonstrated that EPO significantly reduced mortality (RR 0.69, 95% CI 0.49-0.96, p = 0.03) and shortened the hospitalization time (MD -7.59, 95% CI -9.71 to -5.46, p < 0.0001) for patients with TBI. Pooled results of favorable outcome (RR 1.00, 95% CI 0.88-1.15, p = 0.97) and deep vein thrombosis (DVT; RD 0.00, 95% CI -0.05 to 0.05, p = 1.00) did not show a significant difference. CONCLUSIONS The authors suggested that EPO is beneficial for patients with TBI in terms of reducing mortality and shortening hospitalization time without increasing the risk of DVT. However, its effect on improving favorable neurological outcomes did not reach statistical significance. Therefore, more well-designed RCTs are necessary to ascertain the optimum dosage and time window of EPO treatment for patients with TBI.
Keywords: CI = confidence interval; DVT = deep vein thrombosis; EPO = erythropoietin; GOS = Glasgow Outcome Scale; MD = mean difference; RCT = randomized controlled trial; RD = risk difference; RR = risk ratio; TBI = traumatic brain injury; deep vein thrombosis; erythropoietin; favorable neurological outcome; meta-analysis; mortality; traumatic brain injury.
Similar articles
-
Meta-Analysis with Trial Sequential Analysis on the Efficacy and Safety of Erythropoietin in Traumatic Brain Injury: A New Paradigm.World Neurosurg. 2020 Oct;142:465-475. doi: 10.1016/j.wneu.2020.05.142. Epub 2020 May 22. World Neurosurg. 2020. PMID: 32450313 Review.
-
Potential Efficacy of Erythropoietin on Reducing the Risk of Mortality in Patients with Traumatic Brain Injury: A Systematic Review and Meta-Analysis.Biomed Res Int. 2020 Oct 29;2020:7563868. doi: 10.1155/2020/7563868. eCollection 2020. Biomed Res Int. 2020. PMID: 33178833 Free PMC article.
-
Efficacy and safety of erythropoietin for traumatic brain injury.BMC Neurol. 2020 Nov 2;20(1):399. doi: 10.1186/s12883-020-01958-z. BMC Neurol. 2020. PMID: 33138778 Free PMC article.
-
Efficacy and safety of erythropoietin in patients with traumatic brain injury: A systematic review and meta-analysis.Am J Emerg Med. 2019 Jun;37(6):1101-1107. doi: 10.1016/j.ajem.2018.08.072. Epub 2018 Aug 29. Am J Emerg Med. 2019. PMID: 30220640
-
Imaging and serum biomarkers reflecting the functional efficacy of extended erythropoietin treatment in rats following infantile traumatic brain injury.J Neurosurg Pediatr. 2016 Jun;17(6):739-55. doi: 10.3171/2015.10.PEDS15554. Epub 2016 Feb 19. J Neurosurg Pediatr. 2016. PMID: 26894518 Free PMC article.
Cited by
-
Glycans in drug discovery.Medchemcomm. 2019 Jul 26;10(10):1678-1691. doi: 10.1039/c9md00292h. eCollection 2019 Oct 1. Medchemcomm. 2019. PMID: 31814952 Free PMC article. Review.
-
Effect of erythropoietin administration on the expression of brain-derived neurotrophic factor, stromal cell-derived Factor-1, and neuron-specific enolase in traumatic brain injury: A literature review.Ann Med Surg (Lond). 2021 Aug 5;69:102666. doi: 10.1016/j.amsu.2021.102666. eCollection 2021 Sep. Ann Med Surg (Lond). 2021. PMID: 34429948 Free PMC article. Review.
-
Protective Effects of Quercetin on Mitochondrial Biogenesis in Experimental Traumatic Brain Injury via the Nrf2 Signaling Pathway.PLoS One. 2016 Oct 25;11(10):e0164237. doi: 10.1371/journal.pone.0164237. eCollection 2016. PLoS One. 2016. PMID: 27780244 Free PMC article.
-
Comparative safety of multiple doses of erythropoietin for the treatment of traumatic brain injury: A systematic review and network meta-analysis.Front Neurol. 2022 Dec 13;13:998320. doi: 10.3389/fneur.2022.998320. eCollection 2022. Front Neurol. 2022. PMID: 36582613 Free PMC article.
-
A Pro-social Pill? The Potential of Pharmacological Treatments to Improve Social Outcomes After Pediatric Traumatic Brain Injury.Front Neurol. 2021 Aug 19;12:714253. doi: 10.3389/fneur.2021.714253. eCollection 2021. Front Neurol. 2021. PMID: 34489853 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous